Rab Diagnostics secures investment to advance precision cancer diagnostics
We’re excited to share that Rab Diagnostics has secured investment to advance precision cancer diagnostics from Aleap Ventures, Startuplab, Tore Rynning-Nielsen and Hani Mustafa. Combined with recently awarded public grants, this funding enables us to accelerate our development towards new biomarker products long-term. We are thrilled to join forces with expert investors for this journey committed to support our mission of improved precision medicine long term.
This achievement was only possible thanks to a strong team supported by the board, and our wider network. We thank everyone who has been involved in the journey so far.
Rab Diagnostics is pleased to announce it has secured investment from Aleap, Startuplab, Tore Rynning-Nielsen, and Hani Mustafa. Combined with recently awarded public grants, this funding will accelerate planned development activities and support long-term operations as the company advances its mission to improve precision medicine for cancer patients.
"We're fortunate to have the backing of investors who bring both expertise and a shared commitment to transforming cancer care." said Anette Weyergang, CEO. "This support, together with our talented team and advisory network, positions us to deliver meaningful impact for clinicians and patients."
About Rab Diagnostics
Rab Diagnostics develops precision biomarker solutions for next generation targeted chemotherapy (ADCs). Our proprietary RabCancer platform sets a new gold standard for predicting response to ADC therapy. Leveraging science driven deep expertise in intracellular drug trafficking, we partner with biopharma to accelerate clinical development and deliver precision diagnostics to cancer patients.
Learn more at rabdiagnostics.com.
Investment amounts were not disclosed.